Articles citing this paper
A brief survey of interventional agents intended to treat Long COVID
Ross T. Barnard A * and Evan B. Siegel BA
B
![]() Emeritus Professor Ross Barnard is a former Director of the Biotechnology Program at the University of Queensland and a Fellow of the ASM. He was a Principal investigator in the ARC Training Centre for Biopharmaceutical Innovation. He is a member of the editorial board of Microbiology Australia. |
![]() Evan B. Siegel, PhD is CEO of Ground Zero Pharmaceuticals, Inc., which provides regulatory affairs and related consulting services to pharmaceutical and biotechnology firms worldwide. Dr Siegel served in senior positions in pharma and biotechnology. He was a toxicologist at the US FDA and California Department of Health. Dr Siegel is an Adjunct Professor at the University of Queensland, Brisbane, an Adjunct Professor at the Queensland University of Technology, and a visiting professor at the University of California—Irvine, USA. |
Microbiology Australia 45(1) 22-26 https://doi.org/10.1071/MA24008
Submitted: 30 December 2023 Accepted: 16 February 2024 Published: 6 March 2024